Evidence map›Paper›PMID 40866047›Full record

ArticleJACC. Basic to translational science2025

Hypoxanthine Promotes Pulmonary Vascular Remodeling and Adenosine Deaminase Is a Therapeutic Target for Pulmonary Hypertension.

Jun-Zhuo Shi, Yong-Jian Zhu, Meng-Jie Zhang, Yi Yan, Lu-Ling Zhao, Hong-Da Zhang, Yan Liu, Wen-Hui Wu, Zhe Cheng, Chun-Guang Qiu and 7 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Jun-Zhuo ShiSchool of Pharmacy, Henan University, Kaifeng, China; Anesthesiology Department of Huaihe Hospital, Henan University, Kaifeng, China.
Yong-Jian ZhuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Meng-Jie ZhangSchool of Pharmacy, Henan University, Kaifeng, China.
Yi YanHeart Center and Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lu-Ling ZhaoSchool of Pharmacy, Henan University, Kaifeng, China.
Hong-Da ZhangState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yan LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wen-Hui WuDepartment of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhe ChengDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chun-Guang QiuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jie-Jian KouPharmacy Department of Huaihe Hospital, Henan University, Kaifeng, China.
Yun-Feng ZhouSchool of Pharmacy, Henan University, Kaifeng, China.
Xiao-Bin PangSchool of Pharmacy, Henan University, Kaifeng, China.
Ji-Wang ChenCardiovascular Research Center, University of Illinois at Chicago, Chicago, Illinois, USA; Division of Pulmonary, Critical Care Medicine, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Xin-Mei XieSchool of Pharmacy, Henan University, Kaifeng, China.
Yang-Yang HeSchool of Pharmacy, Henan University, Kaifeng, China; Anesthesiology Department of Huaihe Hospital, Henan University, Kaifeng, China. Electronic address: heyangyang@vip.henu.edu.cn.
Zhi-Cheng JingDepartment of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address: jingzhicheng@gdph.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uric acid metabolism is implicated in the pathogenesis of pulmonary arterial hypertension, wherein the key metabolite hypoxanthine exhibits elevated levels, thereby promoting pulmonary vascular remodeling through facilitation of cell proliferation and migration as well as regulation of adenosine triphosphate binding cassette transport signaling pathway. Consequently, therapeutic interventions targeting hypoxanthine synthesis may hold promise for the management of pulmonary arterial hypertension.

Indexed as

drug targethypoxanthinemetabolismpulmonary arterial hypertensionvascular remodeling

Identifiers

PMID40866047
PMCPMC12399150

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.